User login
Key clinical point: Patients with hormone receptor (HR)-positive breast cancer derive survival benefit from treatment with predominantly aromatase inhibitors after chemotherapy.
Major finding: The recurrence-free survival significantly improved in patients who received aromatase inhibitor for greater than 75% of their endocrine treatment duration (adjusted hazard ratio [aHR], 0.63; 95% confidence interval [CI], 0.46-0.86) and overall survival (aHR, 0.50; 95% CI, 0.34-0.74) vs. those who received aromatase inhibitors for less than 25% of their endocrine treatment duration.
Study details: A population-based cohort study of patients with stage I-III, HR-positive invasive breast cancer diagnosed between 2004 and 2007 and received adjuvant chemotherapy and endocrine treatment.
Disclosures: This work was funded by the Netherlands Organization for Health Research and Development, A Sisters Hope, and De Vrienden van UMC Utrecht. Some authors reported research support, grants, advisory fees, and nonfinancial support from various sources outside this work.
Source: Dackus GM et al. J Natl Cancer Inst. 2021 Jun 8. doi: 10.1093/jnci/djab091.
Key clinical point: Patients with hormone receptor (HR)-positive breast cancer derive survival benefit from treatment with predominantly aromatase inhibitors after chemotherapy.
Major finding: The recurrence-free survival significantly improved in patients who received aromatase inhibitor for greater than 75% of their endocrine treatment duration (adjusted hazard ratio [aHR], 0.63; 95% confidence interval [CI], 0.46-0.86) and overall survival (aHR, 0.50; 95% CI, 0.34-0.74) vs. those who received aromatase inhibitors for less than 25% of their endocrine treatment duration.
Study details: A population-based cohort study of patients with stage I-III, HR-positive invasive breast cancer diagnosed between 2004 and 2007 and received adjuvant chemotherapy and endocrine treatment.
Disclosures: This work was funded by the Netherlands Organization for Health Research and Development, A Sisters Hope, and De Vrienden van UMC Utrecht. Some authors reported research support, grants, advisory fees, and nonfinancial support from various sources outside this work.
Source: Dackus GM et al. J Natl Cancer Inst. 2021 Jun 8. doi: 10.1093/jnci/djab091.
Key clinical point: Patients with hormone receptor (HR)-positive breast cancer derive survival benefit from treatment with predominantly aromatase inhibitors after chemotherapy.
Major finding: The recurrence-free survival significantly improved in patients who received aromatase inhibitor for greater than 75% of their endocrine treatment duration (adjusted hazard ratio [aHR], 0.63; 95% confidence interval [CI], 0.46-0.86) and overall survival (aHR, 0.50; 95% CI, 0.34-0.74) vs. those who received aromatase inhibitors for less than 25% of their endocrine treatment duration.
Study details: A population-based cohort study of patients with stage I-III, HR-positive invasive breast cancer diagnosed between 2004 and 2007 and received adjuvant chemotherapy and endocrine treatment.
Disclosures: This work was funded by the Netherlands Organization for Health Research and Development, A Sisters Hope, and De Vrienden van UMC Utrecht. Some authors reported research support, grants, advisory fees, and nonfinancial support from various sources outside this work.
Source: Dackus GM et al. J Natl Cancer Inst. 2021 Jun 8. doi: 10.1093/jnci/djab091.